Catalyst Event
Teva Pharmaceutical Industries Ltd (TEVA) · Other
From KEDI Global Longevity Bio Index (KGLB)
4/29/2026, 12:00:00 AM
On 2026-04-29, Teva announced a definitive agreement to acquire Emalex Biosciences for $700 million upfront. Based on the deal size and pipeline expansion, market analysis estimates a medium market impact (5-10%), estimated.
Korean Translation
2026년 4월 29일 Emalex Biosciences를 7억 달러에 인수하는 최종 계약을 발표함. 거래 규모와 파이프라인 확장을 고려할 때, 시장 분석에 따르면 중간 정도의 시장 영향(5-10%)이 있을 것으로 예상됨.
Related Recent Events
Biogen Inc (BIIB) · Other
FDA PDUFA target action date for LEQEMBI's subcutaneous autoinjector formulation (IQLIK SC-AI) for initiation dosing, a potential new administration option for the Alzheimer's disease treatment, scheduled for 2026-05-24. High impact expected due to the significant market potential of the Alzheimer's treatment.
5/24/2026, 12:00:00 AM
Thermo Fisher Scientific Inc (TMO) · Other
An Investor Day is scheduled for May 20, 2026, where senior management will provide presentations scheduled.
5/20/2026, 12:00:00 AM
Takeda Pharmaceutical Co Ltd (TAK) · Earnings Release
Takeda is scheduled to announce its financial results for the full fiscal year 2025 (ending March 31, 2026) on May 13, 2026. High importance is estimated as earnings reports for major pharmaceutical firms often trigger price movements exceeding 10% based on guidance. This event is scheduled.
5/13/2026, 12:00:00 AM
Natera Inc (NTRA) · Earnings Release
Q1 2026 earnings release is scheduled. Earnings announcements typically result in >5% price impact, scheduled.
5/7/2026, 12:00:00 AM
Viatris Inc (VTRS) · Earnings Release
Viatris is scheduled to report its first quarter 2026 financial results on May 7, 2026, with an estimated price impact of over 5% based on historical earnings volatility scheduled.
5/7/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Earnings Release
Novo Nordisk is scheduled to announce its first quarter 2026 financial results. Low importance as it is a routine earnings call, scheduled.
5/6/2026, 12:00:00 AM